Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FR14S
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,362
Award facts
- Contract value 100% obligated
- $83,362.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $83,362.20 and awarded on January 30, 2026, provides RINVOQ ER 15 mg tablets (30-count units) to the Defense Logistics Agency through a firm fixed-price contract with no set-aside designation. AmerisourceBergen Drug Corp, the prime contractor headquartered in Conshohocken, Pennsylvania, will perform fulfillment at its corporate office location. The award was made competitively and represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with the DLA Troop Support Medical, a $999.999 billion vehicle that extends through December 2031 and serves as the primary mechanism for supplying pharmaceutical products and medical supplies to military healthcare systems globally.
The DLA, a defense agency within the Department of Defense, procures this pharmaceutical supply through its established medical supply chain to support military treatment facilities and veterans' healthcare programs. RINVOQ (upadacitinib) is a targeted synthetic immunosuppressant used primarily for rheumatoid arthritis and inflammatory conditions, representing the type of specialty medication that falls within the comprehensive therapeutic portfolio covered under Cencora's prime vendor agreement. The competitive award to an established pharmaceutical distributor reflects the DLA's strategic approach to ensuring reliable access to critical medications across multiple therapeutic domains for the federal healthcare system.
Quick answers
Who was awarded contract SPE2DR26FR14S?
SPE2DR26FR14S was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FR14S worth?
The government has obligated $83,362 on SPE2DR26FR14S.
Is contract SPE2DR26FR14S an order under another contract?
Yes. SPE2DR26FR14S is a delivery order under SPE2DR25D2003, an indefinite delivery contract.
Was contract SPE2DR26FR14S competed?
The extent of competition for SPE2DR26FR14S was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award